Abstract：Radiotherapy is an important component of combined treatment modality for lymphoma. Radical, consolidation and palliative radiotherapy are recommended in patients with different pathological subtypes and chemotherapy responses. With the development of novel systemic treatment and better understanding of long-term adverse effect with radiotherapy over the past 10 years, tremendous changes have taken place in the target delineation and dose prescription of radiotherapy. This guideline aims at establishing a standardized process in radiotherapy administration, including simulation, target delineation, dose prescription and plan evaluation for common lymphoma subtypes in China based on research evidence and expert opinions, with the purpose of promoting clinical application, improving treatment quality and efficacy as well as reducing adverse effects.
National Cancer Center / National Cancer Quality Control Center. Guideline of target delineation and treatment planning for lymphoma radiotherapy[J]. Chinese Journal of Radiation Oncology, 2022, 31(9): 759-771.
[1] Swerdlow SH,Campo E,Pileri SA,et al.The 2016 revision of the World Health Organization classification of lymphoid neoplasms[J].Blood,2016,127(20):2375-2390.DOI:10.1182/blood-2016-01-643569. [2] Yahalom J,Mauch P.The involved field is back:issues in delineating the radiation field in Hodgkin's disease[J].Ann Oncol,2002,13 Suppl 1:79-83.DOI:10.1093/annonc/13.s1.79. [3] Girinsky T,van der Maazen R,Specht L,et al.Involved‐node radiotherapy (INRT) in patients with early Hodgkin lymphoma:concepts and guidelines[J].Radiother Oncol,2006,79(3):270-277.DOI:10.1016/j.radonc.2006.05.015. [4] Illidge T,Specht L,Yahalom J,et al.Modern radiation therapy for nodal non‐Hodgkin lymphoma‐target definition and dose guidelines from the International Lymphoma Radiation Oncology Group[J].Int J Radiat Oncol Biol Phys,2014,89(1):49-58.DOI:10.1016/j.ijrobp.2014.01.006. [5] Hoppe BS,Hoppe RT.Expert radiation oncologist interpretations of involved‐site radiation therapy guidelines in the management of Hodgkin lymphoma[J].Int J Radiat Oncol Biol Phys,2015,92(1):40-45.DOI:10.1016/j.ijrobp.2015.02.008. [6] Yahalom J,Illidge T,Specht L,et al.Modern radiation therapy for extranodal lymphomas:field and dose guidelines from the International Lymphoma Radiation Oncology Group[J].Int J Radiat Oncol Biol Phys,2015,92(1):11-31.DOI:10.1016/j.ijrobp.2015.01.009. [7] Xu LM,Li YX,Fang H,et al.Dosimetric evaluation and treatment outcome of intensity modulated radiation therapy after doxorubicin‐based chemotherapy for primary mediastinal large B‐cell lymphoma[J].Int J Radiat Oncol Biol Phys,2013,85(5):1289-1295.DOI:10.1016/j.ijrobp.2012.10.037. [8] Xu YG,Qi SN,Wang SL,et al.Dosimetric and clinical outcomes with intensity modulated radiation therapy after chemotherapy for patients with early‐stage diffuse large B‐cell lymphoma of Waldeyer ring[J].Int J Radiat Oncol Biol Phys,2016,96(2):379-386.DOI:10.1016/j.ijrobp.2016.05.023. [9] Liu X,Fang H,Tian Y,et al.Intensity modulated radiation therapy for early‐stage primary gastric diffuse large B‐cell lymphoma:dosimetric analysis,clinical outcome,and quality of life[J].Int J Radiat Oncol Biol Phys,2016,95(2):712-720.DOI:10.1016/j.ijrobp.2016.01.027. [10] Wang H,Li YX,Wang WH,et al.Mild toxicity and favorable prognosis of high‐dose and extended involved‐field intensity‐modulated radiotherapy for patients with early‐stage nasal NK/T‐cell lymphoma[J].Int J Radiat Oncol Biol Phys,2012,82(3):1115-1121.DOI:10.1016/j.ijrobp.2011.02.039. [11] Bi XW,Li YX,Fang H,et al.High‐dose and extended‐field intensity modulated radiation therapy for early‐stage NK/T‐cell lymphoma of Waldeyer's ring:dosimetric analysis and clinical outcome[J].Int J Radiat Oncol Biol Phys,2013,87(5):1086-1093.DOI:10.1016/j.ijrobp.2013.08.040.
2022, Vol. 31 
